CARTCR

PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and…

PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and…

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events: BIO CEO…

Data showed AMP combination with TCR-T cell therapy promotes durable responses against aggressive solid tumors in a mouse model where TCR-T cells alone have no effectAMP combination with TCR-T cell therapy induces marked T cell expansion,…